<section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="kZ_qa s_aA s_aU s_bh s_ay"><div class="kZ_IN s_d8"><a data-test-id="logo" title="Home" class="al_e5 r_Z r_ah" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="al_hR r_Z r_ae"><svg class="al_gx al_fQ al_hN"><use xlink:href="#logo"></use></svg></span></a></div><header class="rS_FM r_Z r_2 r_9 r_ah"><div class="vx_g r_Z r_2 r_9 s_d6 cu_nZ" data-test-id="quick-links"><div class="vx_Wr r_Z r_1 r_ab r_ak s_cH s_b2"><div class="vx_UW s_aR s_av s_ba"><div class="yj_iv" data-test-id="themes-list"><ul class="yj_mY r_Z"><li class="yj_mZ r_Z r_1 s_dW"><a data-test-id="theme-links-item" class="J_eB r_0 r_1 r_6 J_ga J_fx bb_jE bb_jT bb_ka O_G" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="yj_YZ iF_sX">Transcripts</span></span></a></li></ul></div></div></div><div class="vx_Wq r_Z r_1 r_9"></div></div><div class="nd_iW r_Z r_9"><h1 class="nd_ez s_d6 bb_jM bb_j4 bb_ka bb_kX bb_lf bb_lk" data-test-id="post-title">Aadi Bioscience, Inc. (AADI) Q4 2022 Earnings Call Transcript</h1></div><div class="mb-18 flex justify-between text-medium-2-r md:mb-16 rS_RW r_Z r_1" data-test-id="post-page-meta"><div><span class="nd_Lk nd_gW q_W" data-test-id="post-date">Mar. 28, 2023 11:36 AM ET</span><span class="nd_gW q_W" data-test-id="post-primary-tickers"><a class="vy_Ws" href="/symbol/AADI?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAADI">Aadi Bioscience, Inc. (AADI)</a></span></div></div></header><div class="tA_Od r_Z r_2 r_9 s_d6" data-test-id="author-brief"><div class="tA_Z r_Z"><a class="tA_K9 st_K9" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcset="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"></div></a><div class="tA_Oe r_Z r_6 r_ah s_cG"><a class="tA_K9 st_K9 tA_Ja bb_jG bb_jU bb_ka s_dS st_Ja" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="tA_q6 r_Z r_ab"><div class="rG_RF bb_jE bb_jT bb_j9 tA_Oc q_W bb_jE bb_jT bb_j9">141K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="lc_IR" role="none"><button data-state-text="Following" class="J_eB r_0 r_1 r_6 J_fQ J_fA bb_jF bb_jV bb_ka jp_FS s_at s_bx s_aU s_bh px_Hc r_am tA_wi s_ct aX_jo" data-test-id="follow-button" type="button"><span class=""><span class="jp_FU r_Z r_6" data-state-placeholder="Following"><span class="jp_FV">Follow</span></span></span></button></div></div><div class="wx_XY s_d0"><button class="J_eB r_0 r_1 r_6 J_fQ J_fA bb_jF bb_jV bb_ka yv_eB r_0 r_1" data-test-id="play-button" type="button"><span class=""><svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="yv_C7" data-test-id="play-button-play-svg"><path d="M0 16V0l16 8-16 8z" fill="currentColor"></path></svg><span class="yv_pj">Play Earnings Call</span></span></button></div><div><div class="paywall-full-content jc_f r_Z" data-test-id="article-content"><div class="jc_me r_ak"><div class="jc_is jc_EZ" data-test-id="content-container"><p>Aadi Bioscience, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/AADI?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Aadi Bioscience, Inc.">AADI</a></span>) Q4 2022 Earnings Conference Call March 28, 2023 8:30 AM ET</p> <p><strong>Company Participants</strong></p> <p>Marcy Graham - Senior Vice President of Investor Relations and Corporate Communications</p> <p>Neil Desai - Founder and Executive Chairman</p> <p>Scott Giacobello - Interim Chief Executive Officer, President, and Chief Financial Officer</p> <p>Loretta Itri - Chief Medical Officer</p> <p><strong>Conference Call Participants</strong></p> <p>Roger Song - Jefferies LLC</p> <p>Ahu Demir - Ladenburg Thalmann &amp; Company</p> <p><strong>Operator</strong></p> <p>Good day and thank you for standing by. Welcome to the Aadi Bioscience Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.</p> <p>Now I will turn the call over to Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications at Aadi Bioscience. Ms. Graham, please go ahead.</p> <p><strong>Marcy Graham</strong></p> <p>Thank you, Elizabeth. Good morning and welcome to the Aadi Bioscience conference call to review results of the fourth quarter and full year 2022 and to provide an update on our operations and good start in 2023. Joining me on the call today is Scott Giacobello, our CFO and Interim President and CEO who will provide an overview of financial and operational activity during the period, including an update on our continued commercial progress. Next will be our Chief Medical Officer, Dr. Loretta Itri, who will provide insights on our clinical developments and plans for 2023. We will open the line for questions at the end of the call following closing comments.</p> <p class="iW_EQ">Before we get started, a quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other<span class="paywall-full-content invisible"> factors, including those set forth in the Risk Factors section of our annual and quarterly reports filed with the Securities and Exchange Commission which can be found at www.sec.gov or on our website at www.aadibio.com.</span></p> <p class="paywall-full-content invisible">In addition, any forward-looking statements made on this call represent our views only<span class="paywall-full-content no-summary-bullets invisible"> as of today, March 28, 2023 and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.</span></p> <p class="paywall-full-content invisible no-summary-bullets">With that, I will turn the call over to Scott for his opening statements. Scott?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Scott Giacobello</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Marcy and hello everyone. Thank you for joining us this morning to review our financial and operational results for the fourth quarter and full year 2022. As we said before, this past year was a transformational one for Aadi. Those are many. The top line accomplishments of 2022 began early in the year with the successful commercial launch of our first product, FYARRO for the treatment of advanced malignant PEComa, a rare form of sarcoma with no prior standard treatment.</p> <p class="paywall-full-content invisible no-summary-bullets">Upon launch, FYARRO was added to the NCCN Clinical Practice Guidelines as the only preferred treatment regimen for malignant PEComa, and we received a permanent J code for FYARRO soon after, facilitating payer coverage and reimbursement.</p> <p class="paywall-full-content invisible no-summary-bullets">We achieved sales of $15.2 million in 2022 outperforming estimates for the year in just 10 months on the market. This launch was closely followed by the initiation of our Phase 2 registration-directed trial PRECISION 1, a study in patients with solid tumors that have TSC1 or TSC2 inactivating alterations in the mTOR pathway.</p> <p class="paywall-full-content invisible no-summary-bullets">We are excited about the potential for FYARRO to provide benefits for patients beyond PEComa. We believe in our prospects and look forward to sharing preliminary data on a meaningful number of patients in the PRECISION 1 trial in the second quarter of 2023.</p> <p class="paywall-full-content invisible no-summary-bullets">As we progressed on both the commercial and clinical fronts, we announced the completion of a pipe financing of $72.5 million, extending our runway into 2025 and supporting our ongoing operations and further expansion of our initiatives. This includes a collaboration with Mirati Therapeutics announced last fall for a new combination clinical study in patients with KRAS G12C mutations as part of our strategy to expand indications for FYARRO.</p> <p class="paywall-full-content invisible no-summary-bullets">Beyond these advancements, we are pleased with the continued adoption of FYARRO for patients with PEComa. We achieved $5.2 million in sales for the fourth quarter, which represents growth of 23% over Q3. We continued to see increased uptake in the community setting with roughly half of the business now coming from community clinics and hospitals.</p> <p class="paywall-full-content invisible no-summary-bullets">We are encouraged by the acceptance in the market of FYARRO as a leading treatment option and at the end of the year, we had more than 120 unique ordering accounts, up 34% from the prior quarter with a reorder rate of more than 85%, underscoring the positive clinical experience conveyed by healthcare providers who are increasingly viewing FYARRO as the standard of care for their PEComa patients.</p> <p class="paywall-full-content invisible no-summary-bullets">Lastly, we just announced the addition of Dr. Mohammad Hirmand to our Board of Directors. He brings a rich history of success in clinical development and operational expertise to the role, currently serving as the Chief Medical Officer of Avenzo Therapeutics following his role as CMO at Turning Point Therapeutics acquired by BMS last year.</p> <p class="paywall-full-content invisible no-summary-bullets">His impressive qualifications and broad expertise in clinical operations and experiences at companies like Medivation and Peloton compliments the acumen of our existing Board contributors and we are truly looking forward to working with them as we advance the current PRECISION 1 trial and other new trials in the future.</p> <p class="paywall-full-content invisible no-summary-bullets">We are enthusiastic about what has to come in 2023 heading into another year of solid execution, thanks in no small part to our team here at Aadi whose hard work is what made our achievements possible and this continued dedication is what will drive our progress in the future.</p> <p class="paywall-full-content invisible no-summary-bullets">Loretta is up next to further discuss our progress and ongoing clinical activity. Loretta?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Loretta Itri</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Scott, and good morning everyone. On the clinical front, progress continues in our ongoing PRECISION 1 tumor agnostic trial in patients with TSC1 or TSC2 inactivating alterations. The number of open sites has continued to increase along with access to patients allowing us to achieve our goal of opening 120 sites by the end of 2022.</p> <p class="paywall-full-content invisible no-summary-bullets">Patient accrual remains on track, although we continue to deal with widespread staffing shortages as our sites work to recover from the impact of the COVID pandemic. The continuing commitment of our team and our maturing partnerships with the leading next generation sequencing companies, have played a strategic role in affording access to patients.</p> <p class="paywall-full-content invisible no-summary-bullets">This has been an important factor in enabling us to routinely identify eligible patients, particularly in community-based practices. We appreciate our partnerships with U.S. Oncology, Tempus and Foundation Medicine as we work to identify patients who qualify for the trial. We believe that full patient enrollment into this study will be completed within 24 months from first patient treated in the spring of 2024.</p> <p class="paywall-full-content invisible no-summary-bullets">As presented at the recent Society for Gynecologic Oncology Annual Meeting just a few days ago in Tampa, Florida, a sub-analysis of the data from our pivotal AMPECT trial revealed excellent activity for <em>nab</em>-sirolimus in patients presenting with malignant uterine <em>PEComa</em>. Our clinical team has been hard at work building relationships in the GYN oncology community, interacting with clinicians in the field to consider the options made available by <em>nab</em>-sirolimus in treating these patients.</p> <p class="paywall-full-content invisible no-summary-bullets">As we have previously mentioned, we continue to evaluate additional indications for <em>nab</em>-sirolimus beyond sarcoma and TSC1 or TSC2 inactivating alterations, either as a single agent or in combination. We will be providing an update on new potential studies later in the year.</p> <p class="paywall-full-content invisible no-summary-bullets">We are also progressing well in our clinical collaboration with Mirati as we evaluate the combination of adagrasib and <em>nab</em>-sirolimus in KRAS G12C mutants, non-small cell lung cancer and other solid tumors. We expect that Mirati will dose the first patient in this trial during the second quarter of this year.</p> <p class="paywall-full-content invisible no-summary-bullets">As you may recall, we presented preclinical data on the combination of KRAS inhibitors and <em>nab</em>-sirolimus last fall at the AACR-NCI-EORTC meeting that lays the foundation for our partnership on this combination strategy to treat non-small cell lung cancer and other solid tumors with a KRAS G12C mutation. The team here at Aadi is very busy and energized about continuing to explore the further potential benefits of <em>nab</em>-sirolimus in the treatment of patients with additional oncologic indications.</p> <p class="paywall-full-content invisible no-summary-bullets">I will now turn it back over to Scott for a financial update. Scott?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Scott Giacobello</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks Loretta. We had a solid fourth quarter and end the year with a strong performance with approximately $172.6 million in cash, cash equivalents and short-term investments, including proceeds from the completion of our $72.5 million financing last fall. We begin 2023 well capitalized with a balance sheet that is expected to fund operations into 2025.</p> <p class="paywall-full-content invisible no-summary-bullets">Turning to our financial results, FYARRO net product sales amounted to $5.2 million for the fourth quarter and $15.2 million for 2022. As is typical at the end of the year, there was some inventory billed at the specialty distributors in the quarter, and we expect this will normalize in the first quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">Research and development expenses for the quarter increased to $9.4 million as compared to $7.2 million in the prior year quarter. For the year, R&amp;D expense amounted to $32.7 million as compared to $19.7 million last year. This increase is primarily related to the continued progress of the ongoing PRECISION 1 trial and the buildout of the R&amp;D organization.</p> <p class="paywall-full-content invisible no-summary-bullets">Selling, general and administrative expenses for the fourth quarter were $11.1 million compared to $9.7 million in the same period in 2021. For the year SG&amp;A expenses totaled $40.2 million compared to $18.5 million in the prior year. This increase is mainly due to the buildout of our commercial operations and company infrastructure and increased marketing expenses related to the commercial launch of FYARRO.</p> <p class="paywall-full-content invisible no-summary-bullets">Net loss for the fourth quarter was $13.9 million compared to $16 million in the fourth quarter of 2021. Net loss for the year was $60.5 million compared to $110.1 million in the prior year. The prior year included the non-cash impairment charge at $74.2 million related to the acquired contract intangible asset incurred in conjunction with the Aerpio merger. For more information on our financial performance for 2022, a detailed discussion of the results reported on this call will be provided in our 10-K to be filed later today.</p> <p class="paywall-full-content invisible no-summary-bullets">As you've heard today, 2022 was a transformational year for us, one that will set the foundation for the advancements that lie ahead in 2023. Our focus remains on the patients we serve and on providing therapies that improve the lives of those who suffer from mTOR driven diseases.</p> <p class="paywall-full-content invisible no-summary-bullets">We can now open the line for questions. Operator?</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] Our first question comes from the line of Roger Song with Jefferies.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Roger Song</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">That's great. Congrats for the progress and thanks for taking the question. So a couple of questions from us. So the first one is the FYARRO sales looks pretty impressive in terms of the steady grow. Do you have any kind of anecdotal comments in terms of the patient characteristic you're getting on the treatment, such as the line of therapy and the duration on treatment, and the when do you expect you will be able to provide more guidance in terms of the future sales? Thanks</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And great, Roger, thanks for the question. I'll take the first one first, patient characteristics. I would say what we've seen, and I think we've mentioned this before, is early on in the launch of FYARRO in PEComa, we were seeing patients, we were kind of meeting patients where they were in their treatment plan in progress with therapy. And what we've seen after being on the market and physicians being more comfortable and knowing more about the drug as we've moved, we're moving closer to first line, and as we do that, we expect that that's going to have a positive impact on duration. Although I would say that we're still pretty early and just 10 months in on the market and so we'll still need a little more time to see how duration plays out. So I'd say we're probably still a ways away from guidance, but certainly very happy with the progress that we're seeing.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Roger Song</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yep. Yes, thank you. And then so in terms of the PRECISION, this preliminary readout in 2Q, I'm curious what would you consider at the meaningful end, first of all, and also kind of what kind of a venue you will potentially report the data? It will be in the medical meeting or company hosted event or press release? Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. So as far as the -- a meaningful and what we've said is it will not be single digits, so it'll be patients in the double digits. And as far as the venue, it will not be released at a scientific meeting, but rather a company press release or company event.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Roger Song</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Excellent. Thank you. That's it for us and congrats again.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] Our next question comes from the line of Ahu Demir with Ladenburg.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Good morning. Thank you so much for taking my questions. I have two questions. First one is on the revenues. If you could provide more color on the percentage of patients' lives covered and also the re-prescription rate of FYARRO in patients.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. So from a reimbursement perspective, which I think is your first question Ahu, so what we're seeing from a lives covered perspective is that we're north of 85% of commercial lives covered at this point. So quality of access continues to be very strong and we're seeing policies in place without restrictions, so we're very happy with that. And then could you remind me again of your second question?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">My question was, how many patients re-prescribed or how many physicians re-prescribed FYARRO.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yesâ€¦</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Prescription rate?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, Ahu remember, we don't get, we don't really get much in the way of script data. Right? Because FYARRO is an IV therapy and so we don't get patient level data. The best measure we have is really the number of ordering institutions which you can loosely correlate to patients, and that's a launch to date number. But that would be the closest thing we have to actual patient data.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, thanks Scott. And my second question is on the SGO presentation on the relevance of TSC1 and TSC2 alterations in endometrial cancers, could you maybe elaborate more on the relevance, like the maybe percentage of patients who are, who had the TSC1 and TSC2 alterations in endometrial cancers? Is there any specific subtypes that TSC1 and TSC2 alterations are curing those endometrial cancer patients? And maybe the part of the followup question is, what have you shown in the expanded access program for the again, endometrial patients?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, so I'm going to do is, I'm going to turn that first part of your question on the SGO data over to Loretta. Loretta, do you want to handle that one?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Loretta Itri</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. Can you hear me?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Loretta Itri</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi Ahu. So off the top of my head, I can't recall the incidence rates of TSC1 and TSC2 mutations. It is -- of the different tumor types it's one of the higher, I would say, in the range of 3% to 4% of endometrial cancers expressed TSC1 and TSC2 alterations. This sub-analysis that we performed was a relatively small subset of the AMPECT study. But as you may be aware, there was literature to suggest that PEComa's that occurred in patients with endometrial cancer had a relatively unfavorable response. Our data in fact showed a very favorable response of 43% in this population. So I think we have shown rather definitively or at least in the best collection of patients of this type, that the effect of FYARRO in PEComas occurring in endometrial cancer is quite good. Did I answer your question?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, you did. And is there any subtype of endometrial cancer, low grade, high grade, that TSC1 and TSC2 alterations occur at a higher rate?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Loretta Itri</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">We -- unfortunately the number of patients that we had data for would not allow us to say anything definitive in that regard.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I see. Thank you very much.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Neil Desai</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Ahu maybe, this is Neil Desai. Hi, everyone. Maybe I can just jump in here. The -- like Loretta said, we don't have enough information at this point on the sort of copy number high versus low in the relative TSC1 and TSC2 incidents, but that is an area we continue to look. I think you had another question on the EAP and as it relates to endometrial. And if you would recall, we did have endometrial cancer patients and this was not PEComa, but endometrial cancer patients on the EAP data that we had disclosed in ASCO 2021. And at least one of them, I mean, it was a small number, but at least one of them after many lines of therapy had responded and done very well and went on for a long period of time when we did the cutoff for the ASCO data, which was I believe over six months.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ahu Demir</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Very helpful. Thanks for taking my questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] We have a question from the line of [indiscernible] with Cowen.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi thank you for taking my questions. This is [indiscernible] on for Boris Peaker. My first question is regarding PRECISION 1. You mentioned you had some difficulty recruiting due to COVID or staffing shortage. Are we still expecting the final readout in 2024 or if you have any more precise timeline for that?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. Loretta, do you want to take that one?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Loretta Itri</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. Good morning. We as I believe I may have mentioned in my prepared remarks, we are very aware and our sites report that they are having continued problems relative to staffing related to the COVID pandemic. However, we have been able to continue accruing patients onto the trial as we planned. And we do at this point still believe that we will meet our stated goal of completing enrollment in the spring of 2024. So I don't think that there's anything different.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. My second question is regarding to the Mirati collaboration. Could you just give a little more color of like the data expectations?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Scott Giacobello</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. Neil, do you want to take that one?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Neil Desai</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, sure. At this time we haven't really spoken about the timing of data from that, but as Scott mentioned and Loretta mentioned, the timing of the initiation of the trial is in Q2 at this point and that's the information we have from Mirati. It is a Phase 1 trial where, because it's a combination the dose needs to be worked out and so I think we can understand that that takes the usual amount of time for figuring out a combination. So I don't think we expect any results this year, but it's possible we might get something next year. But again, that we have to hear from Mirati.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Thank you for taking my questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">That concludes today's question-and-answer session. I'd like to turn the call back to Scott Giacobello for closing remarks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Scott Giacobello</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, I want to thank everyone for joining us today. As you can see, we're very excited about 2023 and looking forward to sharing more information later in the year. Thank you all.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">This concludes today's conference call. Thank you for participating. You may now disconnect.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="jc_E0" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->AADI<!-- --> <a class="J_eB r_0 r_1 r_6 O_G O_gz" href="/symbol/AADI"><span class="">analysis and news</span></a></li><li class="jc_E0" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="J_eB r_0 r_1 r_6 O_G O_gz" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nb_T r_Z r_9 aX_jo paywall-full-content" data-test-id="post-footer"><span class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8"><button class="ur_CG rz_Rn r_Z r_1 ur_hX" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="ur_fw"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="ur_hG">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="custom-share-button" type="button"><span class="truncate"><span class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="nc_fw"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="nc_hG s_cG">Share</span></span></span></button><button aria-expanded="false" aria-label="Print options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="print-dropdown" type="button"><span class="truncate"><span class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8"><svg viewBox="0 0 14 13" xmlns="http://www.w3.org/2000/svg" class="nc_fw"><path d="M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z"></path></svg><span class="nc_hG s_cG">Print</span></span></span></button><a class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8 nb_Le" data-test-id="comment-button" href="/article/4590644-aadi-bioscience-inc-aadi-q4-2022-earnings-call-transcript#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="nc_fw nb_Lh"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="nc_hG s_cG">Comment</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="recommended-for-you-card-body"><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4637656-sell-everything">Sell Everything</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="lk_a r_Z r_1 r_6" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lk_oX lk_gj"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643307-trade-alert-buy-the-dip-on-this-16-percent-yield-pdi">Trade Alert, Buy The Dip On This 16% Yield: PDI</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Yuval Rotem profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/053/114/293/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643853-visa-and-mastercard-are-on-sale-one-is-more-attractive">Visa And Mastercard Are On Sale, One Is More Attractive</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Yuval Rotem</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Mott Capital Management profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/026/750/043/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643839-the-new-bull-market-is-over">The New Bull Market Is Over</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Mott Capital Management</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Paul Franke profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static2.seekingalpha.com/images/users_profile/017/314/402/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643836-microsoft-take-your-profits-before-they-disappear-rating-downgrade">Microsoft: Take Your Profits Before They Disappear (Rating Downgrade)</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Paul Franke</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Jonathan Weber profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/028/873/105/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643770-medical-properties-trust-q3-earnings-bargain-time">Medical Properties Trust Q3 Earnings: Bargain Time</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Jonathan Weber</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Dividend Sensei profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/047/572/571/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643244-buy-7-percent-yielding-sweet-reit-bargains">Don't Wait To Buy These 7% Yielding Sweet REIT Bargains</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Dividend Sensei</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="lk_a r_Z r_1 r_6" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lk_oX lk_gj"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4640061-billionaire-mark-cuban-says-dividends-create-value-2-great-picks-for-your-retirement">Billionaire Mark Cuban Says Dividends Create Value: 2 Great Picks For Your Retirement</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="The Dividend Collectuh profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/054/869/375/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4640372-perception-is-not-reality-two-reits-buying-all-way-down">Perception Is Not The Reality: 2 REITs I'm Buying All The Way Down</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">The Dividend Collectuh</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Cress profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/050/113/560/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4641618-seeking-alpha-vs-motley-fool">Seek Alpha: Don't Be A Fool</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Steven Cress</span></footer></div></div></div></article></div></div></div></div></section><div class="rK_RL" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="rK_qa"><div class="paywall-full-content"><div class="oY_N0 r_Z r_1 s_eb" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="oY_ez r_Z r_1 bb_jK bb_j0 bb_j9 s_c8 s_dO" data-test-id="comments-counter">Comments</h4><div><button aria-expanded="false" aria-label="Sort By" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="sort-comments-button" type="button"><span class="truncate"><span class="rF_RC r_Z r_1"><span class="rF_RD s_dh ba_jy bb_jF bb_jV bb_j9">Newest</span><div class="sS_SX rF_fw r_Z r_1"><span class="rF_RE"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 rC_Ru s_cC" data-test-id="dropdown" type="button"><span class="truncate"><span class="rC_os r_Z r_1 r_6"><svg class="rC_Rt"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="uE_g qH_g s_d8 aX_jo" data-test-id="add-comment-form"><div class="uE_Qi qH_Qi r_Z"><div class="uE_Fc s_dn"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="uE_Qj qH_Qj"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 uE_Qk qH_Qk s_d6 s_av s_aR s_be s_bz ua_Vh" contenteditable="true" data-test-id="add-comment-input" placeholder="Be the first to comment" role="textbox" tabindex="0"></div><div class="uE_xN qH_xN r_Z r_1 r_7"><button disabled="" class="J_eB r_0 r_1 r_6 J_fQ J_fA bb_jF bb_jV bb_ka uE_Qm qH_Qm s_cM" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div></div><div class="wA_hG s_b5 bb_jF bb_jU bb_j9"><span>To report an error in this transcript<!-- -->, <button class="J_eB r_0 r_1 r_6 yo_Y0" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$-->